Treatment of type 2 diabetes mellitus worldwide Baseline patient characteristics in the global DISCOVER study.pdf (500.53 kB)
Download file

Treatment of type 2 diabetes mellitus worldwide: Baseline patient characteristics in the global DISCOVER study.

Download (500.53 kB)
journal contribution
posted on 24.06.2019, 10:31 by MB Gomes, W Rathmann, B Charbonnel, K Khunti, M Kosiborod, A Nicolucci, SJ Pocock, MV Shestakova, I Shimomura, F Tang, H Watada, H Chen, J Cid-Ruzafa, P Fenici, N Hammar, F Surmont, L Ji, DISCOVER investigators
AIMS: To describe the characteristics and treatment of patients with type 2 diabetes mellitus initiating a second-line glucose-lowering therapy in the global DISCOVER study programme. METHODS: DISCOVER comprises two similar 3-year prospective observational studies (NCT02322762 and NCT02226822), involving 15,992 patients initiating a second-line glucose-lowering therapy in 38 countries across six regions (Africa, Americas, South-East Asia, Eastern Mediterranean, Europe and Western Pacific). RESULTS: Overall, 54.2% of patients were male (across region range [ARR]: 37.7-58.6%). At baseline, mean age and time since diagnosis of type 2 diabetes mellitus were 57.2 (ARR: 53.1-61.9)and 5.6 (ARR: 4.6-6.9) years, respectively. Median glycated haemoglobin (HbA1c) was 63.9 mmol/mol (8.0%; ARR: 7.6-8.3%). Microvascular and macrovascular complications were reported in 18.9% (ARR: 14.5-23.5%) and 12.7% (ARR: 5.0-26.6%) of patients, respectively. First-line treatments were mostly metformin monotherapy (55.6%; ARR: 42.5-83.6%) and combinations of metformin with a sulfonylurea (14.4%; ARR: 5.8-31.1%). The most commonly prescribed second-line therapies were combinations of metformin with a dipeptidyl peptidase-4 inhibitor (23.5%; ARR: 2.2-29.6%) or a sulfonylurea (20.9%; ARR: 13.6-57.1%). CONCLUSIONS: DISCOVER demonstrates considerable global variation in the treatment of type 2 diabetes mellitus, and a need for more aggressive risk factor control.

Funding

The authors would like to thank all investigators and patients participating in the DISCOVER study. Medical writing support was provided by Ste´phane Pintat PhD of Oxford PharmaGenesis, Oxford, UK, and was funded by AstraZeneca.

History

Citation

Diabetes Research and Clinical Practice, 2019, 151, pp. 20-32

Author affiliation

/Organisation/COLLEGE OF LIFE SCIENCES/School of Medicine/Diabetes Research Centre

Version

VoR (Version of Record)

Published in

Diabetes Research and Clinical Practice

Publisher

Elsevier for International Diabetes Federation

eissn

1872-8227

Acceptance date

14/03/2019

Copyright date

2019

Available date

24/06/2019

Publisher version

https://www.sciencedirect.com/science/article/pii/S0168822718317455?via=ihub

Notes

Supplementary data to this article can be found online at https://doi.org/10.1016/j.diabres.2019.03.024.

Language

en

Usage metrics

Categories

Exports